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ABSTRACT
Purpose To evaluate the efﬁcacy and safety of
adalimumab in patients with non-radiographic axial
spondyloarthritis (nr-axSpA).
Methods Patients fulﬁlled Assessment of
Spondyloarthritis international Society (ASAS) criteria for
axial spondyloarthritis, had a Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) score of ≥ 4, total back
pain score of ≥ 4 (10 cm visual analogue scale) and
inadequate response, intolerance or contraindication to
non-steroidal anti-inﬂammatory drugs (NSAIDs); patients
fulﬁlling modiﬁed New York criteria for ankylosing
spondylitis were excluded. Patients were randomised to
adalimumab (N=91) or placebo (N=94). The primary
endpoint was the percentage of patients achieving
ASAS40 at week 12. Efﬁcacy assessments included
BASDAI and Ankylosing Spondylitis Disease Activity
Score (ASDAS). MRI was performed at baseline
and week 12 and scored using the
Spondyloarthritis Research Consortium of Canada
(SPARCC) index.
Results Signiﬁcantly more patients in the adalimumab
group achieved ASAS40 at week 12 compared with
patients in the placebo group (36% vs 15%, p<0.001).
Signiﬁcant clinical improvements based on other ASAS
responses, ASDAS and BASDAI were also detected at
week 12 with adalimumab treatment, as were
improvements in quality of life measures. Inﬂammation in
the spine and sacroiliac joints on MRI signiﬁcantly
decreased after 12 weeks of adalimumab treatment.
Shorter disease duration, younger age, elevated baseline
C-reactive protein or higher SPARCC MRI sacroiliac joint
scores were associated with better week 12 responses
to adalimumab. The safety proﬁle was consistent with
what is known for adalimumab in ankylosing spondylitis
and other diseases.
Conclusions In patients with nr-axSpA, adalimumab
treatment resulted in effective control of disease activity,
decreased inﬂammation and improved quality of life
compared with placebo. Results from ABILITY-1 suggest
that adalimumab has a positive beneﬁt–risk proﬁle in
active nr-axSpA patients with inadequate response to
NSAIDs.
INTRODUCTION
Axial spondyloarthritis may be split into two
categories—ankylosing spondylitis (AS) and non-
radiographic axial spondyloarthritis (nr-axSpA)—
by the 1984 modiﬁed New York criteria which
require the presence of sacroiliitis on plain x-rays
for the classiﬁcation of AS.1 2 With the availability
of MRI, the presence of inﬂammation in the axial
skeleton in the absence of radiographic changes
can now be assessed.2–4 The Assessment of
Spondyloarthritis international Society (ASAS) has
validated new classiﬁcation criteria for patients
with axial SpA5 6 to establish standards that apply
to patients with or without radiographic sacroilii-
tis by including both plain x-rays and MRI as
imaging modalities.5 Although these criteria iden-
tify both AS and nr-axSpA patients, they also
allow the conduct of clinical trials for the treat-
ment of nr-axSpA which is considered an unmet
medical need.5
Registry and clinical trial data indicate that
patients with AS and those with nr-axSpA have
comparable clinical manifestations and burden of
disease, requiring treatment irrespective of the
presence of radiographic damage.7–9 Non-steroidal
anti-inﬂammatory drugs (NSAIDs) are considered
ﬁrst-line therapy for all patients with axial
SpA.10 11 Traditional disease-modifying antirheu-
matic drugs (DMARDs) such as methotrexate and
sulfasalazine are not effective for the treatment of
axial SpA.11–14 Anti-tumour necrosis factor (TNF)
agents are approved therapies for patients with AS
who continue to have active disease despite
NSAIDs. However, for patients with nr-axSpA
there is currently no alternative treatment to
NSAIDs.
New treatment recommendations for patients
with axial SpA, including nr-axSpA, identify
anti-TNF agents as options in patients who fail
NSAIDs;11 however, large phase III trials for this
population have been lacking. Previous clinical
trials conducted prior to the availability of the
ASAS axial SpA criteria employed variable deﬁni-
tions of nr-axSpA and were limited by small
sample sizes; nonetheless, these studies provided
data showing that anti-TNF therapy is also effect-
ive in nr-axSpA.9 15
The present study was developed to further
evaluate the efﬁcacy and safety of adalimumab in
the treatment of patients with nr-axSpA who have
active disease despite treatment with NSAIDs.
This represents the ﬁrst randomised controlled
clinical trial to use the ASAS axial SpA criteria in
classifying patients with nr-axSpA.
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METHODS
Patients
Eligible patients were ≥18 years of age and fulﬁlled ASAS classi-
ﬁcation criteria for axial SpA6 without meeting modiﬁed
New York criteria for AS.1 Patients must have had active
disease, exhibited by a total back pain score of ≥4 on a 0–10 cm
visual analogue scale (VAS) (≥40 on a 0–100 mm VAS) and a
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
score of ≥4. They must also have responded inadequately or
been intolerant to one or more NSAIDs, or had a contraindica-
tion to NSAIDs based on the clinical judgment of the investiga-
tor. Patients with previous or current diagnoses of psoriasis or
psoriatic arthritis or a history of inﬂammatory arthritis of a dif-
ferent aetiology were excluded. Previous exposure to biological
agents was not permitted.
Study design
ABILITY-1 (NCT00939003) was initiated in August 2009 and is
an ongoing phase III randomised placebo-controlled double-
blind trial conducted at 37 centres in Australia, Belgium,
Canada, Czech Republic, France, Germany, Spain, The
Netherlands, the UK and the USA. It was conducted in accord-
ance with International Conference on Harmonization good
clinical practices and the Declaration of Helsinki. Approval of
an institutional ethics review board and voluntary written
informed patient consent were obtained prior to study
procedures.
Eligible patients were centrally randomised using an inter-
active voice response system 1:1 to receive subcutaneous injec-
tions of adalimumab (40 mg every other week) or matching
placebo for 12 weeks during the double-blind period. Efﬁcacy
and safety were assessed at weeks 2, 4, 8 and 12. Patients who
completed the double-blind period were eligible to receive open-
label adalimumab for up to an additional 144 weeks.
Patients could enter the study on concomitant NSAIDs,
prednisone (≤10 mg per day), methotrexate (MTX, ≤25 mg per
week), sulfasalazine (SSZ, ≤3 g per day) and/or hydroxychloro-
quine (≤400 mg per day) or azathioprine (≤150 mg per day, but
not concomitant with any other DMARD) if the doses met
pre-speciﬁed stability requirements prior to randomisation and
remained stable during the ﬁrst 24 weeks except as medically
required due to an adverse event (AE).
Efﬁcacy endpoints
Primary efﬁcacy endpoint
The primary efﬁcacy endpoint was the proportion of patients
who achieved an ASAS40 response at week 12. An ASAS40
response was deﬁned as a ≥40% improvement and an absolute
improvement from baseline of ≥2 units (range 0–10) in ≥3 of
the following four domains: Patient Global Assessment of
Disease Activity (0–10 cm VAS), pain (total back pain, 0–10 cm
VAS), function (Bath Ankylosing Spondylitis Functional Index
(BASFI), 0–10 cm VAS16) and inﬂammation/morning stiffness
(mean score of items 5 and 6 of the BASDAI (0–10 cm VAS))
without any worsening in the remaining domain.17
Secondary efﬁcacy endpoints
Secondary efﬁcacy variables analysed at week 12 included:
ASAS20,18 ASAS partial remission (ASAS PR),18 ASAS5/6,17
BASDAI (0–10 cm VAS), BASDAI50, Ankylosing Spondylitis
Disease Activity Score (ASDAS),19 20 ASDAS clinically import-
ant improvement (ASDAS CII, decrease from baseline ≥1.1),
ASDAS major improvement (ASDAS MI, decrease from
baseline ≥2.0), ASDAS inactive disease (ASDAS ID, score
<1.3),21 Maastricht Ankylosing Spondylitis Enthesitis Score
(MASES, 0–13),22 linear Bath Ankylosing Spondylitis
Metrology index (BASMIlin, 0–10),23 36-Item Short Form V.2
Health Survey (SF-36), Health Assessment Questionnaire
modiﬁed for Spondyloarthropathies (HAQ-S)24 and
Spondyloarthritis Research Consortium of Canada (SPARCC)
MRI scores for the sacroiliac (SI) joints (0–72)25 and the spine
(0–108).26 MRI ﬁlms were scored by two independent central
readers who were blinded to time point and sequence. Average
scores of the readers were used.
Safety assessments
Treatment-emergent AEs were deﬁned as AEs that began or
worsened after the ﬁrst dose of study medication through
70 days after the last dose.
Statistical analysis
Efﬁcacy variables were analysed for all randomised patients
who received at least one dose of blinded study medication, but
excluding seven patients from one site due to investigator non-
compliance. The safety population consisted of all patients
who received at least one dose of study medication.
A target sample size of 194 patients (97 placebo and 97 adali-
mumab) was calculated to provide approximately 90% statis-
tical power to detect a 20% difference in ASAS40 response rates
between the treatment groups, based on a two-sided χ2 test
with a signiﬁcance level of 0.05.
For categorical variables, patients with missing data at week
12 were considered to be non-responders using non-responder
imputation (NRI). Last observation carried forward imputed
values were used for continuous variables. Analysis of covari-
ance (ANCOVA) adjusting for the baseline score was used
to compare change from baseline at week 12 between adalimu-
mab and placebo treatment groups. VAS data were collected on
0–100 mm scales and reported as 0–10 cm data for consistency.
To evaluate the impact of baseline demographics and
disease conditions on the primary efﬁcacy endpoint, ASAS40
response at week 12 was summarised by subgroups of sex
(male, female), race (white, non-white), age (<40, ≥40 years),
weight (<70, ≥70 kg), symptom duration (<5, ≥5 years),
baseline C-reactive protein (CRP) (normal, elevated), concomi-
tant baseline NSAID use (yes, no) or DMARD use (yes, no),
history of inﬂammatory bowel disease (yes, no) or uveitis
(yes, no), baseline HLA-B27 status (positive, negative), past or
current MRI evidence of inﬂammation of the SI joints accord-
ing to the local radiologist/rheumatologist (positive, negative)
and baseline SPARCC SI joint score (<2, ≥2). For subgroup
analyses, a logistic model was used to assess treatment and
subgroup interaction, with a signiﬁcant interaction deﬁned as
p≤0.10.
AEs were summarised as the number and percentage of
patients experiencing AEs using Medical Dictionary for
Regulatory Activities (MedDRA, V.13.1) system organ classes
and preferred terms.
RESULTS
Patients
There were 192 patients randomised into the study. Due to
investigator non-compliance identiﬁed at a single site, seven
patients (three placebo, four adalimumab) were excluded from
all efﬁcacy analyses but were included in safety analyses. Of
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the remaining 185 patients, 94 received placebo and 91 received
adalimumab (ﬁgure 1). Through the 12-week double-blind
period, one patient from each treatment group discontinued
due to AEs. One placebo patient and three adalimumab
patients discontinued for other reasons, which included preg-
nancy, lack of efﬁcacy or violation of entry criteria.
Patient demographics were comparable between the treat-
ment groups (table 1), with no signiﬁcant differences noted
between adalimumab and placebo patients. Over half of the
patients (55%) were women and the mean age across both
groups was 38 years. Despite a mean 10-year history of symp-
toms, the average time since diagnosis was only approximately
3 years prior to study entry.
The most common SpA features included as components of
the ASAS axial SpA criteria noted in the study population were
inﬂammatory back pain, HLA-B27 positivity and a good prior
response to NSAIDs. Despite the absence of radiographic
sacroiliitis, patients with nr-axSpA had high levels of disease
activity as measured by the BASDAI and ASDAS. Furthermore,
there were moderate levels of functional impairment and reduc-
tion in quality of life despite low baseline BASMIlin scores, indi-
cating minimal impairment of spinal mobility. The low mean
MASES score at baseline also indicated that there was limited
involvement or inﬂammation of entheses in the overall study
population, although 72% (133/185) of patients had MASES>0
at baseline (74%, 70/94 placebo; 69%, 63/91 adalimumab).
With the exception of HLA-B27 status, there were no striking
differences between patients who fulﬁlled the imaging arm
(positive MRI sacroiliitis according to the local radiologist/
rheumatologist) and those who fulﬁlled the clinical arm
(HLA-B27 positive/MRI negative) of the ASAS axial SpA cri-
teria (table 1). However, more patients who fulﬁlled the clinical
arm of the ASAS criteria had a family history of SpA. The
SPARCC MRI scores for SI joints were also lower in patients
who fulﬁlled the clinical arm, but the scores for the spine were
comparable across groups.
Efﬁcacy
A signiﬁcantly greater percentage of nr-axSpA patients treated
with adalimumab achieved the primary endpoint of ASAS40
response at week 12 (33/91, 36%) compared with patients
treated with placebo (14/94, 15%; p<0.001, NRI; ﬁgure 2A).
Based on subgroup interaction analyses, symptom duration, age
and baseline CRP status showed signiﬁcant interactions with
treatment on ASAS40 response (p=0.02, p=0.05 and p=0.03,
respectively; NRI). There was a greater treatment effect with
adalimumab among patients with symptom duration <5 years
(ﬁgure 2B), those whose age was <40 years (ﬁgure 2C) and
patients who had elevated CRP levels at baseline (ﬁgure 2D).
HLA-B27 status did not demonstrate a signiﬁcant treatment
interaction with adalimumab (p= 0.42; NRI; ﬁgure 2E).
Patients achieved similar ASAS40 responses with adalimumab
regardless of whether or not they had past or present sacroiliitis
on MRI according to the assessment of the local radiologist/
rheumatologist (p=0.65; NRI). Sensitivity analyses to further
explore the inﬂuence of MRI inﬂammation in the SI joints
were conducted using centrally-read SPARCC scores.
Stratifying patients using the operational classiﬁcation of posi-
tive or negative SI joint MRI inﬂammation based on SPARCC
scores ≥2 or <2 at baseline showed a numerically greater treat-
ment effect of adalimumab in patients with SI joint scores ≥2,
but the interaction was not statistically signiﬁcant (p=0.31;
ﬁgure 2F). However, a signiﬁcant interaction with treatment
was observed based on logistic regression between continuous
SPARCC SI joint scores at baseline and ASAS40 response at
week 12 (p=0.046, NRI; supplementary online Figure S1).
Finally, patients with either a positive MRI (SPARCC score ≥2
for either the SI joints or spine) or an elevated CRP at baseline
demonstrated a greater response to adalimumab compared with
placebo (41% (28/69) adalimumab vs 14% (10/73) placebo), in
contrast to patients who had negative MRI of the SI joints and
spine and a normal CRP at baseline (23% (5/22) adalimumab
vs 20% (4/20) placebo), although the interaction was not statis-
tically signiﬁcant (p=0.13, NRI). Sex, race, weight, concomi-
tant NSAID or DMARD use and history of inﬂammatory
bowel disease or uveitis did not signiﬁcantly affect the response
to adalimumab treatment.
Adalimumab treatment resulted in signiﬁcantly higher percen-
tages of nr-axSpA patients achieving clinical improvements as mea-
sured by ASAS, ASDAS and BASDAI response criteria (ﬁgure 3A).
Signiﬁcantly higher percentages of adalimumab-treated patients
also achieved states of disease remission (ﬁgure 3B), with approxi-
mately one in four patients achieving ASDAS ID after 12 weeks of
treatment with adalimumab.
Adalimumab treatment was associated with statistically sig-
niﬁcant improvements in disease activity of nr-axSpA patients
whether measured by composite indices (ie, BASDAI, ASDAS)
or by individual objective measures of inﬂammation (ie, CRP,
MRI scores) when compared with placebo (table 2). In particu-
lar, there were signiﬁcant decreases in each of the individual
components of the ASAS40 response criteria except for BASFI.
Although there was a numerically greater improvement in
BASFI with adalimumab than with placebo, the difference was
not statistically signiﬁcant. Based on the BASFI component of
Figure 1 ABILITY-1 patient disposition. a ‘Other’ reasons for
discontinuation included lack of efﬁcacy, pregnancy or violation of entry
criteria. One subject in the adalimumab group had a week 12 visit but
discontinued at that visit due to a positive pregnancy test and did not
receive study drug at the week 12 visit.
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the ASAS partial remission criteria, 33% of patients (25/75)
had BASFI <2 at week 12 in the adalimumab group compared
with 11% (9/79) in the placebo group (p=0.001) among
patients with BASFI ≥2 at baseline. Minor decreases in the
BASMIlin and the MASES score were also observed but were
not signiﬁcantly different between treatment groups.
Signiﬁcant improvements in physical function and quality of
life were noted with adalimumab, as determined by the HAQ-S
and SF36 physical component summary scores.
Safety
During the double-blind period, similar proportions of patients in
the two treatment groups experienced any AE or an infectious AE
(table 3). The most common events were nausea (8.2%), diar-
rhoea (7.2%) and upper respiratory tract infection (4.1%) among
patients in the placebo group and nasopharyngitis (11.6%),
nausea (7.4%) and headache (6.3%) in the adalimumab group.
There were few serious AEs. A patient in the placebo group had a
serious AE with symptoms of nausea, vomiting, chills, fever and
Table 1 Baseline demographics and disease characteristics for the full analysis set and subgroups of patients fulfilling the imaging or clinical arms
of the Assessment of Spondyloarthritis international Society axial SpA criteria
All Imaging (MRI+)* Clinical (HLA-B27+, MRI−)†
Placebo
N=94
Adalimumab
N=91
Placebo
N=43
Adalimumab
N=46
Placebo
N=48
Adalimumab
N=45
Demographics
Female, n (%) 54 (57) 47 (52) 22 (51) 26 (57) 29 (60) 21 (47)
White, n (%) 91 (97) 91 (100) 41 (95) 46 (100) 47 (98) 45 (100)
Age (years) 38.4 (10.4) 37.6 (11.3) 38.9 (8.7) 36.8 (9.9) 38.1 (11.7) 38.5 (12.6)
Disease characteristics
Symptom duration (years) 10.1 (8.8) 10.1 (9.0) 10.1 (7.2) 9.3 (9.0) 10.2 (10.1) 11.0 (9.1)
Duration since diagnosis (years) 3.0 (3.8) 2.7 (4.2) 3.2 (4.4) 2.4 (3.9) 3.0 (3.4) 3.1 (4.6)
Concomitant DMARD use, n (%) 16 (17) 17 (19) 6 (14) 5 (11) 9 (19) 12 (27)
Concomitant NSAID use, n (%) 74 (79) 72 (79) 32 (74) 38 (83) 40 (83) 34 (76)
History of SpA features, n (%)
Inflammatory back pain 91 (97) 88 (97) 41 (95) 43 (93) 47 (98) 45 (100)
HLA-B27 positive 70 (74) 75 (82) 22 (51) 30 (65) 48 (100) 45 (100)
Good prior response to NSAIDs 70 (74) 64 (70) 34 (79) 32 (70) 34 (71) 32 (71)
Arthritis (past or present) 49 (52) 32 (35) 22 (51) 16 (35) 24 (50) 16 (36)
Elevated CRP‡ 36 (38) 36 (40) 15 (35) 21 (46) 19 (40) 15 (33)
Heel enthesitis (past or present) 38 (40) 36 (40) 19 (44) 17 (37) 19 (40) 19 (42)
Family history of SpA 23 (25) 28 (31) 6 (14) 9 (20) 17 (36) 19 (42)
Anterior uveitis (past or present) 10 (11) 12 (13) 6 (14) 5 (11) 4 (8) 7 (16)
Dactylitis (past or present) 10 (11) 10 (11) 7 (16) 6 (13) 3 (6) 4 (9)
Inflammatory bowel disease (past or
present)
6 (6) 4 (4) 3 (7) 3 (7) 3 (6) 1 (2)
BASDAI (0–10) 6.5 (1.6) 6.4 (1.5) 6.4 (1.3) 6.2 (1.6) 6.6 (1.7) 6.6 (1.4)
ASDAS 3.4 (0.8) 3.2 (0.8) 3.2 (0.6) 3.3 (0.9) 3.4 (0.9) 3.2 (0.7)
Patient global assessment of disease activity
(0–10 cm VAS)
6.8 (1.9) 6.8 (1.8) 6.7 (1.9) 6.8 (1.9) 6.8 (1.8) 6.7 (1.7)
Total back pain (0–10 cm VAS) 7.0 (1.7) 6.9 (1.8) 6.9 (1.8) 7.0 (1.9) 6.9 (1.7) 6.8 (1.7)
BASFI (0–10 cm VAS) 4.9 (2.3) 4.5 (1.9) 4.6 (2.3) 4.4 (2.1) 5.0 (2.3) 4.6 (1.8)
Inflammation/morning stiffness§ (0–10) 6.7 (2.1) 6.5 (2.0) 6.5 (1.9) 6.3 (2.0) 6.8 (2.3) 6.6 (1.9)
CRP¶ (mg/l) 7.6 (10.2) 6.8 (11.8) 6.3 (9.1) 7.4 (9.7) 8.8 (11.3) 6.2 (13.8)
Elevated baseline CRP, n (%) 37 (39) 29 (32) 15 (35) 18 (39) 20 (42) 11 (24)
MASES (0–13) 3.9 (3.4) 3.5 (3.6) 3.6 (3.4) 4.0 (3.8) 4.2 (3.5) 2.8 (3.5)
BASMIlin (0–10) 2.7 (1.2) 2.7 (1.3) 2.6 (1.1) 2.6 (1.3) 2.7 (1.1) 2.8 (1.2)
SF-36 PCS (0–100) 33.1 (8.3) 33.9 (7.7) 32.9 (7.9) 34.0 (7.5) 33.3 (8.6) 33.8 (8.0)
HAQ-S (0–3) 1.1 (0.6) 1.0 (0.6) 1.1 (0.6) 1.0 (0.6) 1.1 (0.5) 1.0 (0.5)
SPARCC MRI sacroiliac joint score (0–72) 4.7 (9.9) 5.1 (9.5) 7.3 (12.9) 8.5 (12.1) 2.5 (5.7) 1.6 (3.5)
SPARCC MRI spinal score (0–108) 4.6 (6.3) 4.1 (5.3) 4.4 (6.5) 4.5 (6.3) 4.6 (6.2) 3.6 (3.9)
All values are mean (SD) unless otherwise indicated.
N: ASDAS, 91/87 placebo/adalimumab; BASFI, 90 adalimumab; BASMI, 90 adalimumab; SPARCC SI, 91 placebo, SPARCC spine, 90 placebo.
*Past or present sacroiliitis on MRI suggestive of axial SpA6 based on assessment by the local radiologist/rheumatologist.
†Patients who did not have past or present sacroiliitis on MRI based on assessment by the local radiologist/rheumatologist but were HLA-B27 positive; after randomisation,
three patients were found to have neither a positive MRI nor a positive HLA-B27.
‡Based on data obtained in the medical history for the presence of CRP concentration above upper normal limit in the presence of back pain.
§Mean of BASDAI questions 5 and 6.
¶Combined CRP levels including both standard CRP that has been converted to mg/l units and high-sensitivity CRP values.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index;
BASMIlin, Bath Ankylosing Spondylitis Metrology Index-linear; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MASES, Maastricht Ankylosing
Spondylitis Enthesitis Score; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory drugs; SpA, spondyloarthritis; SPARCC, Spondyloarthritis Research
Consortium of Canada; VAS, visual analogue scale.
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dizziness. Three serious AEs were reported in the adalimumab
group: breast dysplasia, induced abortion and acute hepatitis. The
acute hepatitis was reported by the investigator as probably due
to isoniazid for tuberculosis prophylaxis as the baseline visit
laboratory tests prior to the ﬁrst dose of study drug but after
starting isoniazid showed elevated liver function tests. The case
of acute hepatitis was one of four hepatic-related AEs in the adali-
mumab group; all other hepatic-related AEs were isolated liver
function test abnormalities that were not associated with a deﬁn-
ite diagnosis or liver pathology. There were no malignancies,
opportunistic infections, tuberculosis, lupus-like syndrome,
demyelinating disease or deaths through week 12.
DISCUSSION
This study is the ﬁrst clinical trial to incorporate the ASAS
axial SpA criteria in classifying nr-axSpA patients and the
largest randomised controlled trial of an anti-TNF therapy in
this population. Results from this study provide important
insights into the characteristics of patients with nr-axSpA and
the potential beneﬁts of adalimumab therapy. First, the level of
disease activity of nr-axSpA patients enrolled in this study was
similar to those of AS patients who participated in randomised
controlled trials of anti-TNF therapies. Second, signiﬁcant clin-
ical improvement was observed in nr-axSpA patients treated
with adalimumab compared with placebo after just 12 weeks
of therapy. Third, consistent with previous reports, the clinical
response to adalimumab treatment in nr-axSpA patients was
greater in patients with shorter symptom duration, younger
age or presence of elevated CRP at baseline.
The nr-axSpA population enrolled in this study was younger
and had a greater proportion of women compared with AS
populations in randomised controlled trials of anti-TNF
Figure 2 Percentage of patients achieving Assessment of Spondyloarthritis international Society 40 response at week 12. (A) Full analysis set;
*p<0.001 for comparison of treatment response between adalimumab versus placebo. (B) Patients with symptom duration <5 years or ≥5 years.
(C) Patients with age <40 years or ≥40 years. (D) Patients with or without elevated C-reactive protein (CRP) at baseline. (E) Patients with presence
or absence of HLA-B27. (E) Patients with SPARCC SI joint score <2 or ≥2 at baseline. Non-responder imputation.
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therapies.8 27 28 However, these observations are consistent
with what has been reported for other nr-axSpA cohorts,
including the patient population that was evaluated to validate
the ASAS axial SpA criteria.6 7 9 29 There was an average delay
of 7 years between onset of symptoms to diagnosis in
nr-axSpA patients in this study, which highlights the need for
better ways to identify these patients. Despite the absence of
radiographic sacroiliitis and the above differences in demo-
graphics compared with AS patients, patients with nr-axSpA
who continued to have symptoms of active disease despite
NSAIDs had comparable levels of disease activity to that of
patients with AS according to BASDAI, ASDAS and total back
pain.8 9 27 28 However, a smaller proportion of patients with
nr-axSpA had elevated CRP at baseline compared with AS
patients, and mean MRI SPARCC scores for the SI joints and
spine at baseline were lower than previous reports in patients
with AS.8 27 28 30
The study met its primary endpoint with 36% of patients in
the adalimumab group achieving ASAS40 response at week 12
compared with 15% in the placebo group. ASAS40 is a more
stringent measure of response than ASAS20 typically used in
AS trials. Treatment effect with adalimumab was also signiﬁ-
cant when other composite measures were used (ie, ASAS20,
ASAS 5/6, BASDAI50, ASDAS). More importantly, clinical
remission was achieved by more patients in the adalimumab
arm than in the placebo arm, whether deﬁned by ASAS PR or
ASDAS ID. The clinical efﬁcacy of adalimumab was further
supported by signiﬁcant improvements in objective measures of
inﬂammation (ie, CRP and the SPARCC MRI scores for both SI
joints and spine). Although improvements in functionality and
quality of life were noted based on the SF36 physical compo-
nent summary score and HAQ-S, improvement in BASFI and
BASMIlin did not meet statistical signiﬁcance. This could be
attributed in part to the relatively low baseline BASFI and
BASMIlin scores. These results conﬁrm previous ﬁndings from
smaller trials of anti-TNF agents in nr-axSpA. In a randomised
controlled trial of 46 patients with nr-axSpA, adalimumab
therapy resulted in signiﬁcantly better ASAS40 responses at
week 12 compared with placebo.9 Likewise, in 40 patients with
inﬂammatory back pain for 3 months to 3 years, HLA-B27 posi-
tivity and MRI evidence of sacroiliitis, patients receiving inﬂixi-
mab had signiﬁcantly greater reduction in BASDAI and MRI
scores than those on placebo at week 16.15
Subgroup analyses of the interaction between certain base-
line characteristics and treatment showed that patients whose
symptom duration was <5 years, age <40 or baseline CRP was
elevated were more likely to achieve ASAS40 at week 12 with
adalimumab. Similar observations have been reported in estab-
lished AS 31–33 and were noted in a randomised controlled trial
of adalimumab in 46 patients with active axial SpA without
radiographically-deﬁned sacroiliitis: patients with disease dur-
ation ≤3 years, age ≤30 or CRP>6 mg/l at baseline had a
greater probability of achieving ASAS40 or BASDAI50 at week
52.9 These ﬁndings further emphasise the need to diagnose
patients earlier. No other baseline variables evaluated had an
impact on treatment response, including HLA-B27 status and
past or present sacroiliitis on MRI according to the ASAS cri-
teria, suggesting that adalimumab is a potential treatment
option for nr-axSpA patients regardless of whether they fulﬁl
the imaging or clinical arm of the ASAS axial SpA criteria.
Figure 3 (A) Percentage of patients with clinical response. (B)
Percentage of patients with disease remission. Non-responder
imputation. *p≤0.001 for comparison of treatment response between
adalimumab versus placebo except Assessment of Spondyloarthritis
international Society 20 (ASAS20) (p=0.004) and ASAS PR (p=0.01).
ASDAS CII, clinically important improvement; ASDAS MI, major
improvement; ASAS PR, partial remission; ASDAS ID, inactive disease.
Table 2 Clinical, functional and imaging endpoints at week 12
Variable
Placebo N=94 Adalimumab
N=91
p Value
Mean change
from baseline
Mean change
from baseline
BASDAI (0–10) −1.0 −1.9 0.004
ASDAS −0.3 −1.0 <0.001
Patient global assessment of
disease activity (0–10 cm VAS)
−0.9 −2.2 <0.001
Total back pain (0–10 cm VAS) −1.1 −2.3 <0.001
BASFI (0–10 cm VAS) −0.6 −1.1 0.053
Inflammation/morning stiffness −1.1 −2.2 <0.001
CRP (mg/l) −0.3 −4.3 <0.001
BASMIlin (0–10)* −0.1 −0.1 0.828
MASES (0–13)* −0.8 −0.6 0.962
HAQ-S Disability index (0–3)* −0.1 −0.3 0.025
SF-36 PCS (0–100)* 2.0 5.5 0.001
SPARCC MRI SI score (0–72)* −0.6 −3.2 0.003
SPARCC MRI spinal score
(0–108)*
−0.2 −1.8 0.001
p Value for between-group comparisons based on ANCOVA adjusted for baseline;
last observation carried forward analyses unless otherwise noted.
N placebo/adalimumab: BASFI, 94/90; ASDAS, 91/87.
*Observed analyses (N placebo/adalimumab): BASMIlin (93/90); MASES (93/91);
HAQ-S (90/88); SF-36 PCS (93/91); SPARCC MRI SI (84/84); SPARCC MRI spine
(83/85).
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis
Functional Index; BASMIlin, linear Bath Ankylosing Spondylitis Metrology Index;
CRP, C-reactive protein; HAQ-S, Health Assessment Questionnaire modified for
Spondyloarthropathies; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score;
MRI, magnetic resonance imaging; SF-36 PCS, Short Form-36, V.2, Health Status
Survey, Physical Component Summary Score; SI, sacroiliac; SPARCC,
Spondyloarthritis Research Consortium of Canada.
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However, patients with active inﬂammation of the SI joints
based on a SPARCC score ≥2 at baseline showed a numerically
(although non-signiﬁcant) higher response, and increasing base-
line SPARCC SI joint scores were associated with a greater like-
lihood of clinical response. These ﬁndings suggest that the
greater the extent of SI joint inﬂammation, the more likely a
patient may beneﬁt from adalimumab treatment. There was
also a trend indicating better responses in patients with either
inﬂammation of the SI joints or spine or an elevated CRP at
baseline. Thus, objective evidence of active inﬂammation at
baseline, such as presence of a positive MRI or an elevated CRP
level, seems to be a good predictor of treatment response to
adalimumab.
Adalimumab was well tolerated during the double-blind
period of this study. There were no notable imbalances in the
occurrence of AEs between treatment groups. Safety data are
consistent with what is known about the safety proﬁle of ada-
limumab in AS and other immune-mediated diseases.8 34
Limitations of this study include the duration of the double-
blind period, which does not allow for longer term comparison
of the efﬁcacy of adalimumab therapy with placebo in
nr-axSpA patients who continue to have active disease despite
NSAIDs. This study was not designed to evaluate if adalimu-
mab therapy can prevent progression from nr-axSpA to AS.
The trial was also not powered for subgroup analyses, which
were further limited by uneven distribution of patients in
certain subgroups (eg, HLA-B27 status). In addition, the
outcome measures used in this study were validated for AS and
have not been speciﬁcally developed and validated for a
nr-axSpA population. As patients with nr-axSpA and those
with AS are part of the same disease spectrum of axial SpA
and have similar disease manifestations, the use of previously
developed outcome measures for AS in this study of nr-axSpA
patients was deemed to be appropriate.
In summary, 12 weeks of adalimumab therapy in patients
with nr-axSpA resulted in signiﬁcant clinical improvements
compared with placebo, providing additional evidence that
adalimumab controls inﬂammation with a similar safety
proﬁle across a range of spondyloarthritides. Efﬁcacy and
safety results from this study suggest that adalimumab is an
appropriate treatment option for active nr-axSpA patients
who fail NSAIDs, especially those with objective evidence of
inﬂammation. Longer term data would provide information
on the optimal use of adalimumab in patients with
nr-axSpA.
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